ANI Pharmaceuticals will acquire Alimera Sciences in a deal that values the firm at $381m in upfront consideration, after signing a definitive agreement in a move that is seen as an effort to gain a foothold in ophthalmology and expand its rare diseases business.
ANI will pay $5.50 per share in cash at closing, with one non-tradable contingent value right representing the right to receive up to $0